玩股撇步(動畫小學堂)  

  • 理想的成長型公司, 本業EPS的成長幅度會大於營收的成長幅度
  • 營收到某個數字後, 本業EPS呈現不成比例的增加, 有可能是規模經濟的效應
  • 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
  • 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
  • 如果EPS衰退,要觀察同業是不是有一樣的狀況
  • 要留意增資減資和公司債對股本及EPS的影響
成長能力-近8季
加權平均股數 QoQ YoYEPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY營收 QoQ YoY毛利率(%) QoQ YoY營業利益率 QoQ YoY稅後淨利率 QoQ YoY營業利益 QoQ YoY稅後淨利 QoQ YoY稅前淨利率(%) QoQ YoY稅後淨利率(%) QoQ YoY兩季平均(YOY)營收成長率(%)兩季平均(YOY)EPS成長率(%)兩季平均(YOY)本業EPS成長率(%)
26Q1 (8)299-0.33-0.330.29-9.38-21.620.01-96.15-87.50.29-72.38-21.626.29-23.7616.9153.91-4.84-0.8612.07-31.263.2518.9814.96-11.140.76-47.5920.630.87-10.31-22.3225.6428.14-8.0718.9814.96-11.144.3329.52-33.08
25Q4 (7)3000.00.00.3268.4239.130.2630.0-29.731.0545.8356.728.2532.428.9856.65-0.280.9817.563.91-2.9316.5157.8480.241.4538.15.840.9770.1842.6520.0122.3962.9516.5157.8480.2414.2843.598.48
25Q3 (6)3000.0900.00.1918.75-90.310.20-13.0417.650.7235.85-83.786.23-3.8620.556.810.535.7716.9044.6927.0710.4638.91-8.01.0538.1652.170.5718.75-3.3916.3593.2611.5310.4638.91-8.08.29-19.0087.23
25Q2 (5)3000.01263.640.16-56.76-94.680.23187.527.780.5343.24-84.136.4820.4529.656.513.920.3211.68-0.09-26.497.53-64.75-43.850.7620.63-3.80.48-57.14-28.368.46-69.67-53.597.53-64.75-43.85--0.00
25Q1 (4)3000.00.00.3760.870.00.08-78.380.00.37-44.780.05.38-28.930.054.38-3.070.011.69-35.380.021.36133.190.00.63-54.010.01.1264.710.027.89127.120.021.36133.190.0--0.00
24Q4 (3)300900.00.00.23-88.270.00.37117.650.00.67-84.910.07.5746.420.056.104.450.018.0936.020.09.16-19.440.01.3798.550.00.6815.250.012.28-16.230.09.16-19.440.0--0.00
24Q3 (2)3036.360.01.96-34.880.00.17-5.560.04.4432.930.05.173.40.053.71-4.650.013.30-16.30.011.37-15.210.00.69-12.660.00.59-11.940.014.66-19.580.011.37-15.210.0--0.00
24Q2 (1)220.00.03.010.00.00.180.00.03.340.00.05.00.00.056.330.00.015.890.00.013.410.00.00.790.00.00.670.00.018.230.00.013.410.00.0--0.00
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2026/42.24-8.1818.238.5317.36.58N/A-
2026/32.4428.9319.716.2916.976.290.68-
2026/21.89-3.046.323.8515.296.280.68-
2026/11.95-19.5625.571.9525.578.290.52-
2025/122.43-37.8514.2626.3318.08.250.5-
2025/113.91104.618.9923.918.397.880.53-
2025/101.91-7.490.1319.9920.426.040.69-
2025/92.06-0.1514.5418.0823.066.230.64-
2025/82.07-1.2916.5316.0224.256.540.61-
2025/72.09-11.8631.0313.9525.486.680.6-
2025/62.387.747.7511.8624.556.480.5-
2025/52.2116.3633.499.4819.836.140.53-
2025/41.9-7.028.967.2716.235.720.57-
2025/32.0414.576.45.3819.035.380.52因為子公司大研生醫去年3月業績有一次性因素導致基期較低,所以今年3月YoY較高,主要是基期較低因素導致
2025/21.7814.5110.023.34-0.75.460.51-
2025/11.56-26.8-10.681.56-10.687.270.39-
2024/122.13-40.7119.2622.317.547.620.32-
2024/113.5887.9625.6620.186.447.290.34-
2024/101.915.820.5316.63.045.480.45-
2024/91.81.578.3314.693.375.170.6-
2024/81.7710.990.5812.892.724.980.63-
2024/71.6-0.614.3511.123.074.860.64-
2024/61.61-2.692.219.522.865.00.56-
2024/51.65-5.02-1.717.912.995.070.56-
2024/41.7450.5115.716.264.315.040.56-
2024/31.683.575.565.0412.085.04N/A-
2024/21.62-7.0411.143.3615.645.14N/A-
2024/11.74-2.2620.171.7420.176.38N/A-
2023/121.78-37.5316.720.7413.046.53N/A-
2023/112.8550.3731.618.9612.716.41N/A-
2023/101.914.0329.5716.119.915.32N/A-
2023/91.66-5.6820.5914.217.734.96N/A-
2023/81.7615.1523.3212.556.234.87N/A-
2023/71.53-2.655.4710.793.884.79N/A-
2023/61.57-6.43-0.99.253.624.76N/A-
2023/51.6811.824.927.684.64.77N/A-
2023/41.5-5.326.146.04.514.55N/A-
2023/31.599.0511.214.493.974.49N/A-
2023/21.460.516.552.910.44.43N/A-
2023/11.45-5.09-5.11.45-5.15.14N/A-
2022/121.53-29.55-7.318.3511.425.16N/A-
2022/112.1748.0622.3316.8213.55.01N/A-
2022/101.466.120.214.6612.34.27N/A-
2022/91.38-3.54-0.0213.1913.824.26N/A-
2022/81.43-1.510.8911.8115.694.47N/A-
2022/71.45-8.533.9610.3818.084.64N/A-
2022/61.59-0.9410.968.9320.754.61N/A-
2022/51.613.1216.117.3423.14.45N/A-
2022/41.42-0.821.585.7425.24.21N/A-
2022/31.434.4720.184.3226.434.32N/A-
2022/21.37-10.4824.092.8929.774.54N/A-
2022/11.53-7.2835.311.5335.314.95N/A-
2021/121.65-7.0335.6916.4760.064.88N/A因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有累計虧損,長期來看需謹慎觀察
2021/111.7721.2753.3714.8263.324.61N/A因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有累計虧損,長期來看需謹慎觀察
2021/101.465.8887.5313.0564.774.26N/A因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察
2021/91.38-2.6567.0311.5962.294.19N/A因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察
2021/81.421.4881.0910.2161.674.25N/A因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察
2021/71.4-2.3874.188.7958.924.21N/A因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察
2021/61.433.6572.557.456.340.0N/A因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察
2021/51.3818.4668.725.9652.890.0N/A因直播成長與大研生醫熱銷,惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高,尚有大額累計虧損,長期來看需謹慎觀察
成長能力-近5年
加權平均股數 YoYEPS YoY本業EPS YoY營收 YoY毛利率(%) YoY營業利益率 YoY稅後淨利率 YoY營業利益 YoY稅前淨利 YoY稅後淨利 YoY
2025 (5)299-0.331.0556.720.7713.2426.3318.2856.194.1914.7620.6913.8652.483.8943.014.7274.813.1456.22
2024 (4)3001263.640.67-94.990.68-33.3322.267.9553.93-7.8412.23-32.219.09-37.052.72-26.882.7-26.232.01-32.55
2023 (3)220.013.3720.891.0229.1120.6212.3758.522.9718.0411.714.447.63.7225.683.6619.612.9821.14
2022 (2)2246.6711.06-32.560.79-7.0618.3511.2156.835.9716.15-15.3613.42-12.02.96-6.033.06-1.922.46-1.6
2021 (1)150.016.4034.650.8537.116.560.3553.63019.08015.2503.1528.573.1227.872.535.14

財務分析相關資訊

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。